Longeveron Inc. (LGVN)
NASDAQ: LGVN · Real-Time Price · USD
1.580
-0.120 (-7.06%)
At close: Mar 28, 2025, 4:00 PM
1.616
+0.036 (2.27%)
After-hours: Mar 28, 2025, 7:56 PM EDT

Company Description

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States.

Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 1 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer’s disease, as well as in phase 2b clinical trial to treat aging frailty.

The company was incorporated in 2014 and is headquartered in Miami, Florida.

Longeveron Inc.
Longeveron logo
Country United States
Founded 2014
IPO Date Feb 12, 2021
Industry Biotechnology
Sector Healthcare
Employees 25
CEO Mohamed Wa'el Hashad

Contact Details

Address:
Life Science & Technology Park, Suite 520
Miami, Florida 33136
United States
Phone 844 470 2550
Website longeveron.com

Stock Details

Ticker Symbol LGVN
Exchange NASDAQ
Stock Type Common Stock
Share Class Class A Shares
Fiscal Year January - December
Reporting Currency USD
IPO Price $10.00
CIK Code 0001721484
CUSIP Number 54303L104
ISIN Number US54303L1044
Employer ID 47-2174146
SIC Code 2834

Key Executives

Name Position
Mohamed Wa'el Ahmed Hashad M.B.A. Chief Executive Officer and Director
Dr. Joshua Michael Hare FACC, M.D. Co-Founder, Chief Science Officer and Chairman
Lisa A. Locklear M.B.A. Chief Financial Officer, Executive Vice President and Treasurer
Paul T. Lehr J.D. General Counsel and Secretary
Devin Blass Chief Technology Officer and Senior Vice President of Chemistry, Manufacturing, and Controls
Dr. Nataliya Agafonova M.D. Chief Medical Officer
Lisa McClain-Moss Vice President of Manufacturing
Brian G Rash Ph.D. Vice President of Research and Discovery
Heather Zhou Vice President and Corporate Controller

Latest SEC Filings

Date Type Title
Mar 28, 2025 S-3 Registration statement under Securities Act of 1933
Mar 14, 2025 8-K Current Report
Feb 28, 2025 8-K Current Report
Feb 28, 2025 10-K Annual Report
Jan 30, 2025 8-K Current Report
Nov 27, 2024 144 Filing
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024 8-K Current Report
Nov 12, 2024 10-Q Quarterly Report
Aug 14, 2024 8-K Current Report